Financials in USD. Standardized financial statements.
A compact view of how Nuo Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.31M | $1.37M | $608,525 | $112,250 | $0 | $0 | $146,177 | $1.37M | $721,045 | $2.20M |
| Revenue Growth? | +142.7% | +124.3% | +442.1% | 0.0% | 0.0% | -100.0% | -89.3% | +90.1% | -67.3% | 0.0% |
| Cost of Revenue? | $1.10M | $302,842 | $126,092 | $19,214 | $0 | $0 | $114,614 | $162,993 | $1.09M | $1.99M |
| Gross Profit? | $2.22M | $1.06M | $482,433 | $93,036 | $0 | $0 | $31,563 | $1.21M | -$369,997 | $216,978 |
| Gross Margin? | +66.9% | +77.8% | +79.3% | +82.9% | 0.0% | 0.0% | +21.6% | +88.1% | -51.3% | +9.8% |
| Operating Expenses? | $4.73M | $3.52M | $3.65M | $3.41M | $90,670 | $378,059 | $1.00M | $2.71M | $5.86M | $8.59M |
| Operating Income? | -$2.52M | -$2.46M | -$3.17M | -$3.32M | -$90,670 | -$378,059 | -$969,198 | -$1.50M | -$15.53M | -$8.37M |
| EBITDA? | -$2.36M | -$2.36M | -$3.06M | -$3.10M | $0 | -$288,200 | -$879,339 | -$1.40M | -$13.85M | -$6.75M |
| Income Before Tax | -$2.51M | -$2.32M | -$3.17M | -$3.17M | -$90,670 | -$90,870 | -$1.19M | -$1.54M | -$14.98M | $22.48M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$2.51M | -$2.32M | -$3.17M | -$3.03M | -$90,670 | -$139,260 | -$1.42M | -$1.54M | -$14.98M | $22.48M |
| EPS? | $-0.05 | $-0.05 | $-0.08 | $-0.08 | $-0.00 | $-0.01 | $-0.06 | $-0.07 | $-1.02 | $2.26 |
| Diluted EPS? | $-0.05 | $-0.05 | $-0.08 | $-0.08 | $-0.00 | $-0.01 | $-0.06 | $-0.07 | $-1.02 | $2.26 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality